Business
Aeterna Zentaris Reports Updated Phase 1 Trial Results for AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer at ASCO GCS Meeting
QUÉBEC CITY, Feb. 3, 2012 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:&#x...
About this update from Cosciens Biopharma Inc.
[{"type":"text","content":"\n\n\n\n\n\nQUÉBEC CITY, Feb. 3, 2012 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the \"Company\") today reported positive updated\n results for the Phase 1 portion of its ongoing Phase 1/2 study in\n castration- and taxane-resistant prostate cancer (CRPC) with AEZS-108 (zoptarelin doxorubicin), the\n Company's targeted cytotoxic luteinizing hormone-releasing hormone\n (LHRH) analog. Data showed that AEZS-108 was well tolerated and\n demonstrated early evidence of antitumor activity in men with CRPC.\n Data were presented by Jacek Pinski, MD, PhD, Associate Professor of\n Medicine at the Norris Comprehensive Cancer Center of the University of\n Southern California, during a poster session at the American Society of\n Clinical Oncology Genitourinary Cancers Symposium which is being held\n in San Francisco. Prior interim data on this study were presented at\n the European Society of Medical Oncology Congress in September 2011.\n The trial is being supported by a three-year US$1.6 million grant from\n the National Institutes of Health to Dr. Pinski.\n\n\nDr. Pinski stated, \"Overall, AEZS-108 has been very well tolerated in\n this heavily pre-treated population, though we have met some\n hematologic toxicity at the higher dose levels. The efficacy of this\n agent, even at lower doses, is impressive and we are eager to complete\n the Phase 1 and begin the Phase 2 portion of the study.\"\n\n\nJuergen Engel, PhD, President and CEO of Aeterna Zentaris added, \"It is\n very encouraging to see that AEZS-108 continues to show good safety and\n interesting efficacy data even at this early stage. This compound is a\n key element of our personalized medicine approach in oncology, and the\n dedicated work of Dr. Pinski and his team ideally fits our commitment\n to develop a novel targeted treatment for men suffering from prostate\n cancer.\"\n\n\nThe Phase 1/2 Study\n\n\nThe poster #D3 titled, \"A Phase 1 Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate\n Cancer\", S.V. Liu, A.V. Schally, T.B. Dorff, D.D. Tsao-Wei, S.G. Groshen, S.\n Xiong, D. Hawes, D.I. Quinn, Y.C. Tai, N.L. Block, J. Engel, J. K.\n Pinski, (NCT01240629), detailed the use of AEZS-108, in patients with\n pre-treated CRPC. This is a single-arm study with a Phase 1 lead-in\n portion (testing 3 dose levels) to a Phase...